A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.

Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.

A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.